{"entity":{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","aka":[],"tldr":"Filippo de Braud heads medical oncology and the phase 1 programme at Italy's national cancer institute.","summary":"Filippo de Braud is Director of Medical Oncology and Hematology at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan and Professor at the University of Milan. His specialisms are medical oncology, early-phase trials and gastrointestinal cancers, and he heads the phase 1 programme at Italy's national cancer institute. His papers include the combined phase I results of the pan-TRK, ROS1 and ALK inhibitor entrectinib from the ALKA-372-001 and STARTRK-1 trials, a Cancer Discovery study showing a fasting-mimicking diet is safe and reshapes metabolism and antitumour immunity in patients with cancer, and the CheckMate 032 trial of nivolumab alone or with ipilimumab in recurrent small-cell lung cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Braud%20F%5BAuthor%5D%20phase%20I"}],"tags":[],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Medical Oncology and Hematology, INT Milan; Professor, University of Milan","institutionId":"int-milan","specialisms":["Medical oncology","Early-phase trials","Gastrointestinal cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Braud%20F%5BAuthor%5D%20phase%20I"}],"papers":[{"title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)","journal":"Cancer Discovery","year":2017,"doi":"10.1158/2159-8290.cd-16-1237"},{"title":"Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer","journal":"Cancer Discovery","year":2021,"doi":"10.1158/2159-8290.cd-21-0030"},{"title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30098-5"}],"orcid":"0000-0003-0103-730X"},"route":"/people/filippo-de-braud/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"institution":[{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","route":"/institutions/int-milan/"}]}}